On October 25, "Kangwei Century," a portfolio company invested in by the sub-fund backed by Yuanhe Chencun Management's flagship fund and managed by Fenxiang Investment, was listed on the STAR Market, with stock code: 688426.

Founded in 2010, Kangwei Century is dedicated to the independent research and development of core underlying technologies in molecular diagnostics. With over a decade of R&D expertise in areas such as enzyme raw materials, nucleic acid preservation, and sample pre-processing, the company has become one of the few domestic biotech firms that have achieved a comprehensive business layout across all critical stages of molecular testing. Its flagship products include molecular detection enzyme raw materials, nucleic acid preservation reagents, nucleic acid extraction and purification kits, and molecular diagnostic test kits—each playing a vital role in enhancing the efficiency and accuracy of molecular testing. Leveraging its technological strengths in these key molecular testing processes, Kangwei Century has expanded its business into screening and diagnostic solutions for gastrointestinal diseases and respiratory infectious diseases, developing a range of innovative products and services. This strategic move has enabled the company to establish an integrated system encompassing "core enzyme raw materials + test kits + testing services" for molecular diagnostics.

Kangwei Century has been deeply rooted in the molecular diagnostics industry for many years, leveraging independent R&D and product innovation to achieve comprehensive technological coverage across key molecular testing processes. The company has established six core technology platforms—enabling enzymes, nucleic acid preservation, nucleic acid extraction & purification, fluorescence quantitative PCR, gene sequencing, and nucleic acid mass spectrometry—which collectively encompass 23 cutting-edge technologies. Building on its robust technical expertise, Kangwei Century has successfully integrated reagents and services into every stage of molecular diagnostics, from nucleic acid sample collection and extraction/purification to final detection. Additionally, the company has mastered the in-house production of core raw materials essential for molecular testing.

Leveraging its deep-rooted technological expertise in the field of molecular diagnostics, Kangwei Century has not only established a comprehensive portfolio of reagents and services spanning the entire process—from nucleic acid sample preservation and purification to final detection—but also ensured that several of its commercially available products deliver performance metrics equal to or surpassing those of comparable imported counterparts.

In the future, the company will continue to develop cutting-edge molecular detection technologies while refining its core expertise in molecular testing reagents. Focused on detecting gastrointestinal diseases and respiratory infectious illnesses, we will create innovative molecular diagnostic products and services.